Tumors with dominant FGFR2 amplification included STAD (4.09%), OV (1.88%), pheochromocytoma and paraganglioma (PCPG) (1.12%), ESCA (0.55%), and PAAD (0.54%). This evidence concerns the gene FGFR2 and paraganglioma.